



PATIENT INFORMATION: Fax completed form, insurance information, and clinical documentation to (720) 862-0405

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_

Patient Status:  New to Therapy  Continuing Therapy Next Treatment Date: \_\_\_\_\_

MEDICAL INFORMATION:

Patient Weight: \_\_\_\_\_ lbs. Patient Height: \_\_\_\_\_ Allergies: \_\_\_\_\_

ICD-10: \_\_\_\_\_ Diagnosis: \_\_\_\_\_

- Checkboxes for various medical conditions: Rheumatoid Arthritis, Osteoporosis, Psoriatic Arthritis, etc.

THERAPY ORDER

Table with columns Drug and Dosing. Rows include Actemra, Benlysta, Briumvi, Cimzia, Cosentyx, Entyvio, Evenity, Ilumya, Infliximab (Remicade/Avsola/Renflexis), and Krystexxa.

|   |  |
|---|--|
| <b>Nulojix</b>                              | <input type="checkbox"/> Initial phase: IV: 10 mg/kg on day 1 (day of transplant, prior to implantation) and on day 5 (-96 hours after day 1 dose), followed by 10 mg/kg at the end of week 2, week 4, week 8, and week 12 following transplantation<br><b>OR</b><br><input type="checkbox"/> Maintenance phase: IV: 5 mg/kg every 4 weeks beginning at the end of week 16 following transplantation<br><b>OR</b><br>Other: _____  |
| <b>Ocrevus</b>                              | <input type="checkbox"/> Loading Dose: 300mg IV at 0 and 2 weeks, then 600mg IV every 6 months<br><b>OR</b><br><input type="checkbox"/> 600mg IV every 6 months  |
| <b>Orencia</b>                              | <input type="checkbox"/> Dose: _____ mg IV (<60 kg: 500 mg; 60 to 100 kg: 750 mg; >100 kg: 1 g)<br><b>AND</b><br>Frequency:<br><input type="checkbox"/> 0, 2, 4 weeks, and every 4 weeks<br><input type="checkbox"/> Every 4 weeks   |
| <b>Prolia</b>                               | <input type="checkbox"/> 60 mg SQ every 6 months   |
| <b>Reclast (Zoledronic Acid)</b>            | <input type="checkbox"/> 5 mg IV x 1   |
| <b>Rituximab (Rituxan/Truxima/Ruxience)</b> | <input type="checkbox"/> Infuse Rituxan <b>OR</b> rituximab biosimilar as required by patient's insurance<br><b>OR</b><br><input type="checkbox"/> Do not substitute. Infuse the following rituximab product: _____<br><b>AND</b><br>DOSE: <input type="checkbox"/> 1000mg <input type="checkbox"/> 375mg/m <sup>2</sup> <input type="checkbox"/> 500mg<br><b>AND</b><br>Frequency:<br><input type="checkbox"/> One time dose<br><input type="checkbox"/> Day 0, repeat dose in 2 weeks, then repeat course every _____ weeks <b>OR</b> _____ months x _____ refill(s)<br><input type="checkbox"/> Day 0, repeat dose in 2 weeks. One time order, do not repeat the course.<br><input type="checkbox"/> Weekly x 4 weeks<br><input type="checkbox"/> Every 6 months x _____ refill(s)<br><input type="checkbox"/> Other: _____ |
| <b>Saphnelo</b>                             | <input type="checkbox"/> 300mg IV every 4 weeks  |
| <b>Simponi Aria</b>                         | <input type="checkbox"/> 2mg/kg IV at weeks 0, 4, and then every 8 weeks (initial dosing)<br><b>OR</b><br><input type="checkbox"/> 2mg/kg IV every 8 weeks x 1 year  |
| <b>Stelara</b>                              | Initial Infusion:<br><input type="checkbox"/> ≤55kg (<120 lbs) 260 mg IV x 1 dose<br><input type="checkbox"/> 55kg to 85kg (121 lbs. to 187 lbs.) 390mg IV x 1 dose<br><input type="checkbox"/> >85kg (>187lbs.) 520mg IV x 1 dose   |
| <b>Tepezza</b>                              | <input type="checkbox"/> 10mg/kg IV for the first infusion, followed by 20mg/kg IV (3 weeks after the initial dose) every 3 weeks for 7 additional infusions (8 total infusions)   |
| <b>Vyepti</b>                               | <input type="checkbox"/> 100mg IV every 3 months<br><b>OR</b><br><input type="checkbox"/> 300mg IV every 3 months  |
| <b>Other/Specific Instructions:</b>         | Dose: _____<br>Frequency: _____  |

**Premedication orders:** Tylenol  1000mg  500mg PO

Diphenhydramine 25-50mg PO/IV  Loratadine 10mg PO  Cetirizine 10mg  Cetirizine 10mg IVP

**Additional premedications:**  Solu-Medrol \_\_\_\_\_ mg IVP  Solu Cortef \_\_\_\_\_ mg IVP  Other \_\_\_\_\_

**Lab orders:** \_\_\_\_\_ **Lab frequency:** \_\_\_\_\_

**PROVIDER INFORMATION**

By signing this form and utilizing our services, you are authorizing DAC and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies and to select the preferred site of care for the patient:

Provider Name: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Provider NPI: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_

**PREFERRED LOCATION**

**Lowry Denver, CO**  
7111 E Lowry Blvd #200, Denver CO 80230

**Lone Tree, CO**  
9695 S Yosemite St #120, Lone Tree, CO 80124



**PATIENT INFORMATION:** Fax completed form, insurance information, and clinical documentation to (720) 862-0405

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

**REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL**

- Include signed and completed order (MD/prescriber to complete page 1)
- Include patient demographic information and insurance information
- Include patient's medication list
- Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
  - For biologic orders, has the patient had a documented contraindication/intolerance or failed trial of a conventional therapy (i.e., steroids)?  Yes  No  
If yes, which drug(s)? \_\_\_\_\_
  - For biologic orders, does the patient have a contraindication/intolerance or failed trial to any other biologic?  Yes  No  
If yes, which drug(s)? \_\_\_\_\_
- Include labs and/or test results to support diagnosis
- If applicable - Last known biologic therapy: \_\_\_\_\_ and last date received: \_\_\_\_\_. If patient is switching to biologic therapies, please perform a wash-out period of \_\_\_\_\_ weeks prior to starting ordered biologic therapy.
- Other medical necessity: \_\_\_\_\_

**REQUIRED PRE-SCREENING (DRUG THERAPY)**

- TB screening test completed within 12 months - attach results**
  - Positive  Negative
- Hepatitis B screening (Hepatitis B surface antigen) -  Positive  Negative**
- Hepatitis B core antibody total (not IgM) -  Positive  Negative**
- Serum immunoglobulins - attach results** Recommended for: rituximab

\*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Denver Arthritis Clinic will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

**Please fax all information to (720) 862-0405 or call (303) 302-7426**